Corticotroph carcinoma presenting as a silent corticotroph adenoma

Pituitary

Volumn 6, Issue 1, 2003, Pages 41-47

  Farrell, William E ^a   Coll, Anthony P ^c   Clayton, Richard N ^a   Harris, Philip E ^b  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Allelic loss; Pituitary carcinoma; Polyclonality

Indexed keywords

ANDROGEN RECEPTOR; CARBOPLATIN; CORTICOTROPIN; DEXAMETHASONE; DNA; ETOPOSIDE; HYDROCORTISONE; METYRAPONE; OCTREOTIDE; PHOSPHOGLYCERATE KINASE; TUMOR SUPPRESSOR PROTEIN; VINCRISTINE;

ADULT; ALLELE; ARTICLE; BRAIN SURGERY; CASE REPORT; CHROMOSOME INACTIVATION; CLONAL VARIATION; DNA DETERMINATION; FEMALE; GENETIC ANALYSIS; GENETIC SCREENING; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS CARCINOMA; HYPOPHYSIS TUMOR; MALIGNANT TRANSFORMATION; METASTASIS; MICROSATELLITE MARKER; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TANDEM REPEAT; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT FAILURE; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; X CHROMOSOME;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; ADULT; CUSHING SYNDROME; DIAGNOSIS, DIFFERENTIAL; DOSAGE COMPENSATION, GENETIC; FATAL OUTCOME; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; PITUITARY NEOPLASMS;

EID: 0345688682     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026233927714     Document Type: Article

References (24)

1. Kovacs K, Scheithauer B, Horvath E, Lloyd R. The World Health Organization classification of adenohypophyseal neoplasms; a proposed five-tier scheme. Cancer 1996;78:502.
2. Ogilvy KM, Jakubowski J. Intracranial dissemination of pituitary adenomas. J Neurol Neurosurg Psych 1973;36: 199.
3. Winkelman NW, Cassel C, Schlesinger B. Intracranial tumors with extracranial metastases. J Neuropathol Exp Neurol 1952;11:149.
4. D'Abrera VSE, Burke WJ, Bleasel KF, Bader L. Carcinoma of the pituitary. J Pathol Bacteriol 1973;109:335.
5. Epstein JA, Epstein BS, Molho L, Zimmerman HM. Carcinoma of the pituitary gland with metastases to the spinal cord and roots of the cauda equina. J Neurosurg 1964;21:846.
6. Martins AN, Hayes GJ , Kempe LH . Invasive pituitary adenomas. J Neurosurg 1965;22:268.
7. Cohen H , Dible H. Pituitary basophilism associated with a basophil carcinoma of the anterior lobe of the pituitary gland. Brain 1936;59:395.
8. Forbes W. Carcinoma of the pituitary gland with metastases to the liver in a case of Cushing's syndrome. J Pathol Bact 1947;59:137.
9. Sheldon WH, Golden A , Bondy PK. Cushing's syndrome produced by a pituitary basophil carcinoma with hepatic metastases. Am J Med 1954;17:134.
10. Salassa RM, Kearns TP, Kernohan JW, Sprague RG, MacCarty CS. Pituitary tumours in patients with Cushing's syndrome. J Clin Endocrinol Metab 1959;19:1523.
11. Queiroz L de S, Facure NO, Facure JJ, Modesto NP, Lopes de Faria J. Pituitary carcinoma with liver metastases and Cushing's syndrome. Arch Pathol 1975;99:32.
12. Kaiser FE, Orth DN, Mukai K, Oppenheimer JH. A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides. J Clin Endocrinol Metab 1983;57:649.
13. Casson IF, Walker BA, Hipkin LJ, Davis JC, Buxton PH, Jeffreys RV. An intrasellar pituitary tumour producing metastases in liver, bone and lymph glands and demonstration of ACTH in the metastatic deposits. Acta Endocrinol 1986;111:300.
14. Asa SL, Ezzat S. The cytogenetics and pathogenesis of pituitary adenomas. Endocrine Revs 1998;19:798.
15. Vaughan NJA, Laroche CM, Goodman I, Davies MJ, Jenkins JS. Pituitary Cushing's disease arising from a previously non-functional corticotroph adenoma. Clin Endocrinol 1985;22:147.
16. Bates AS, Buckley N, Boggild MD, Bicknell EJ, Perrett CW, Broome JC, Clayton RN. Clinical and genetic changes in a case of Cushing's carcinoma. Clin Endocrinol 1995;42:663.
17. Bates AS, Farrell WE, Bicknell EJ, McNicol AM, Talbot AJ, Broome JC, Perrett CW, Thakker RV, Clayton RN. Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997;82:818.
18. Pei L, Melmed S, Scheithauer B, Kovaks K, Benedict WE, Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (Rb) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumour supressor gene other than Rb. Cancer Research 1995;55:644.
19. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN, Farrell WE. Chromosome 13q deletion mapping in pituitary tumours: Infrequent loss of the retinoblastoma susceptibility gene (Rb1) locus despite loss of Rb1 protein product in somatotrophinomas. Cancer Research 1999;59:1562.
20. Farrell WE, Simpson D, Bates AS, Talbot JA, Bicknell J, Clayton RN. Chromosome 9p deletions in invasive and non invasive non-functional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 gene. Cancer Research 1997;57:2703.
21. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P, Perrett CW, Thakker RV, Clayton RN. Molecular genetic studies of sporadic pituitary tumours. J Clin Endocrinol Metab 1994;78:387.
22. Gilliland DG, Blanchard KL, Levy J, Perrin S, Bunn HF. Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 1991;88:6848.
23. Clayton RN, Pfeifer M, Atkinson AB, Belchetz P, Wass JA, Kyrodimou E, Vanderpump M, Simpson D, Bicknell J, Farrell WE. Different patterns of allelic loss (loss of heterozygosity) in recurrent human pituitary tumors provide evidence for multiclonal origins. Clin Cancer Res 2000;6:3973.
24. van Kamp H, Jansen R, Willemze R, Fibbe WE, Landegent JE. 1991 Studies on clonality by PCR analysis of the PGK-1 gene. Nucleic Acids Res 1991;19:2794.